Assessment of Mediastinal Masses With Diffusion Weighted MR Imaging

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03214341

Enrollment

Registered

2017-07-11

Start date

2017-12-01

Completion date

2019-12-30

Last updated

2017-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mediastinal Tumor

Keywords

mediastinal masses, MRI diffusion

Brief summary

Differentiation between benign and malignant mediastinal tumors as well as characterization and grading of malignancy which is essential for treatment planning as well as for prognosis

Detailed description

Differentiation between benign and malignant mediastinal tumors as well as characterization and grading of malignancy is essential for treatment planning as well as for prognosis . MRI presents valuable diagnostic information in assessing the mediastinum. In addition, special applications have been developed over recent years diffusion-weighted magnetic resonance imaging is one such technique The advent of echo-planar imaging technique has rendered diffusion weighted imaging of the abdomen and thoracic cavity possible . Quantitative assessment of the mediastinal mass is possible by calculation of apparent diffusion co-efficient value ,which is related to the proportion of extracellular and intracellular component. The apparent diffusion co-efficient is inversely correlated with tissue cellularity. It is lower in viable tumor tissue with densely packed diffusion-hindering obstacles than in tissue with less densely packed obstacles such as tumor necrosis and benign tissue .

Interventions

RADIATIONMRI diffusion

using MRI diffusion to differentiate between benign and malignant mediastinal masses

Study design

Observational model

CASE_CROSSOVER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Any age groups * diagnosis of mediastinal mass (by Multislice Computed Tomography).

Exclusion criteria

* chemotherapy radiotherapy. * thoracic surgery. * cystic mass . * mass with large amount of necrosis or calcification. * contraindication of MRI (e.g. pacemakers , claustrophobia).

Design outcomes

Primary

Measure	Time frame
sensitivity and specificity of magnetic resonance imaging diffusion in mediastinal masses	up to one month

Countries

Egypt

Contacts

Primary ContactNoha Mohammed Ali Attia, lecturer

nohamohammedali@yahoo.com00201001238435

Backup ContactMostafa Thabet Hussein, professor

Thabet.mostafa@yahoo.com00201122999878

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026